Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2004 • ACR Convergence 2022
Which Route and Dose of Corticosteroids Is Most Effective in Inducing Remission in Early Rheumatoid Arthritis? A Systematic Literature Review and Meta-analysis
Laura Parker¹ and Nicola Gullick², ¹University of Warwick, Coventry, United Kingdom, ²University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom
Background/Purpose: Current NICE guidance for rheumatoid arthritis (RA) states that glucocorticoids may be used for bridging therapy and to rapidly decrease inflammation in acute flares1.…
Abstract Number: 2182 • ACR Convergence 2022
mRNA Vaccine Against Fibroblast Activation Protein Ameliorates Murine Models of Inflammatory Arthritis
Xiaowei Zhang¹, Antony Jozic¹, Pingfang Song¹, Qiang Xu², Xiaofei Shi³, Hong Wang⁴, Lindsey Bishop¹, Hillary Struthers¹, John Rutledge⁵, Shuang Chen¹, Fei Xu¹, Meaghan Hancock¹, Daocheng Zhu⁶, Gaurav Sahay¹ and Cong-Qiu Chu¹, ¹Oregon Health & Science University, Portland, OR, ²Guangzhou University of Chinese Medicine, Guangzhou, China, ³Henan University of Science and Technology, Luoyang, China, ⁴Wenzhou Medical University, Wenzhou, China, ⁵Portland VA Research Foundation, Portland, ⁶Shanghai Kexin Biotechnology, Shanghai, China
Background/Purpose: Synovial fibroblasts in patients with rheumatoid arthritis (RA) contribute substantially to the perpetuation of synovitis and invasion to cartilage and bone, and have been…
Abstract Number: 2249 • ACR Convergence 2022
Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study
Gabriel Figueroa Parra¹, Emily Gilbert², Maria Valenzuela Almada¹, Sebastian Vallejo¹, Matthew Neville³, Naomi Patel⁴, Claire Cook⁵, Xiaoqing Fu⁵, Ramla Hagi⁵, Gregory McDermott⁶, Michael Dilorio⁶, Lucy Masto⁶, Kathleen Vanni⁶, Emily Kowalski⁶, Grace Qian⁶, Zachary Wallace⁵, Ali Duarte-Garcia¹ and Jeffrey Sparks⁷, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Jacksonville, FL, ³Mayo Clinic, Phoenix, AZ, ⁴Massachusetts General Hospital, Sale Creek, TN, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) has been associated with severe COVID-19, but few studies have investigated outcomes in RA phenotypes such as interstitial lung disease (RA-ILD),…
Abstract Number: 0060 • ACR Convergence 2022
Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission
Jeffrey Curtis¹, Kathleen Fox², Fenglong Xie³, Yujie Su³, David Collier⁴, Cassie Clinton³ and Hafiz Oko-osi⁵, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Strategic Health (formerly with Amgen), Thousand Oaks, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Amgen Inc., Simi Valley, CA, ⁵Gilead Sciences, Foster City, CA
Background/Purpose: Rheumatoid arthritis (RA) affects about 1-2% of adults with annual US costs at $19 billion. Most studies evaluating cost of care have not had…
Abstract Number: 0118 • ACR Convergence 2022
Sex-Based Variations in Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions
Cheryl Barnabe¹, Patrick McLane², Nadia Luca¹, Katie Lin¹, Kelsey Chomistek¹, Meghan Elliott¹, Shanon McQuitty³, Eileen Davidson³, Clare Hildebrandt⁴, Steven Katz², Brian Holroyd² and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Patient and Family Advisors, Alberta Health Services, Calgary, AB, Canada
Background/Purpose: High quality ambulatory care provision should mitigate avoidable emergency department (ED) visits by persons with inflammatory arthritis (IA) conditions and address the unique realities…
Abstract Number: 0241 • ACR Convergence 2022
Inequity in Disease Impact Between Male and Female Rheumatoid Arthritis Patients
Gonul Hazal Koc¹ and Pascal de Jong², ¹Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, the Netherlands, Rotterdam, Netherlands, ²ErasmusMC, Hendrik Ido Ambacht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is more common in females than males. Moreover, males and females may have different disease courses and burdens, but data on…
Abstract Number: 0257 • ACR Convergence 2022
High Density Lipoprotein Bound miR-1246 Is Enriched in Patients with Rheumatoid Arthritis and Is Proinflammatory
Qiong Wu, Quanhu Sheng, Danielle Michell, Kasey Vickers and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: High density lipoprotein (HDL) is known for its anti-atherogenic cholesterol efflux and antioxidant functions. HDL has additional relevance to rheumatoid arthritis (RA) because of…
Abstract Number: 0273 • ACR Convergence 2022
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderately to Severely Active RA
Kevin Winthrop¹, Daniel Aletaha², Roberto Felice Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Paul Van Hoek⁶, Christopher Watson⁷, Pieter-Jan Stiers⁶, Vijay Rajendran⁸, Katrien Van Beneden⁶, jacques-eric gottenberg⁹ and Gerd Burmester¹⁰, ¹Oregon Health & Science University, Portland, OR, ²Medical University Vienna, Wien, Austria, ³University of Milan, Milano, Italy, ⁴University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁵Keio University and Saitama Medical University, Tokyo, Japan, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos Biotech Ltd, Cambridge, United Kingdom, ⁸Galapagos NV, Gent, Belgium, ⁹Strasbourg University Hospital, Strasbourg, France, ¹⁰Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is a second-generation oral Janus kinase 1 preferential inhibitor approved in Europe, Japan, and the UK for treatment of RA.1,2 Over a…
Abstract Number: 0291 • ACR Convergence 2022
Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients
Naga Prabu¹, velammal petchaippan², Gayathri anand³, Aswathi kumar¹ and Saranya Ramachandiran³, ¹SAKTHI RHEUMATOLOGY CENTRE PVT LTD, Coimbatore, India, ²PSG INSTTUTE OF MEDICAL SCIENCES AND RESEARCH, Coimbatore, India, ³sakthi rheumatology centre pvt l;td, Coimbatore, India
Background/Purpose: Tofacitinib(Tofa) an oral Janus kinase inhibitor(JAK) has shown good promise in the management of rheumatoid arthritis and psoriatic arthritis. While being increasingly used in…
Abstract Number: 0309 • ACR Convergence 2022
Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study
Eugen Feist¹, Evgeny Nasonov², Michael Luggen³, Saeed Fatenejad⁴, Sergey Grishin⁵, Mikhail Samsonov⁶ and Roy Fleischmann⁷, ¹Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³University of Cincinnati College of Medicine, Cincinnati, OH, ⁴SFC Medica, LLC, Charlotte, NC, ⁵R-Pharm, Moscow, Russia, ⁶R-Pharm JSC, Moscow, Russia, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Olokizumab (OKZ), an IL-6 ligand inhibitor, demonstrated significant improvements in signs and symptoms of RA vs placebo (PL) and non-inferiority to adalimumab (ADA).1-2 Patients…
Abstract Number: 0531 • ACR Convergence 2022
Development and Performance of a Diagnostic Precision Biomarker for Seronegative Rheumatoid Arthritis Based on DNA Methylation in Blood
Espen Riskedal¹, Karl Trygve Kalleberg¹, Arne Søraas², Maria Dahl Mjaavatten³, Grethe-Elisabeth Stenvik⁴, Joe Sexton⁴, Janis Neumann¹, Cathrine Lund Hadley¹, Guro Goll⁴, Silje Watterdal Syversen⁴, Håkon Bøås⁵, Jennifer Ruth Harris⁵, Astanand Jugessur⁵, Siri Lillegraven⁴ and Espen Haavardsholm⁴, ¹Age Labs AS, Oslo, Oslo, Norway, ²Age Labs AS, Eiksmarka, Norway, ³Diakonhjemmet Hospital, Haslum, Norway, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Norwegian Institute of Public Health, Oslo, Norway
Background/Purpose: Patients with seronegative rheumatoid arthritis (RA) exhibit no detectable antibodies, often resulting in delayed diagnosis and treatment initiation. A blood-based test, capable of detecting…
Abstract Number: 0589 • ACR Convergence 2022
Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation
Carlos Pérez-Sánchez¹, Adrián Llamas Urbano², Tomás Cerdó², Laura Muñoz-Barrera¹, Ismael Sánchez-Pareja², Luz Marina Sánchez-Mendoza³, Nuria Barbarroja¹, María Carmen Ábalos-Aguilera⁴, Juan Antonio Moreno⁵, María isabel Burón⁶, José Antonio González-Reyes⁵, Pilar Font¹, Jerusalem Calvo-Gutierrez², Marta Rojas-Gimenez¹, Eduardo Collantes¹, Alejandro Escudero-Contreras², José Manuel Villalba-Montoro⁶ and Chary Lopez-Pedrera¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain, Córdoba, Spain, ⁴Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁵Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Córdoba, Spain, ⁶Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain
Background/Purpose: This study aimed to: 1- Evaluate the levels of NAD+ and gene transcripts involved in its metabolism in Rheumatoid Arthritis (RA) patients. 2- Analyse…
Abstract Number: 0605 • ACR Convergence 2022
Citrullinated Peptide-Specific ACPA Are Present in the Female Genital Tract in Premenopausal Women with and Without RA
Daniele Marcy¹, Heather Rothfuss², Ashley Visser¹, Jill Norris³, V. Michael Holers⁴, Kevin D Deane⁵, William Robinson⁶, Brian Cherrington² and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Wyoming, Laramie, ³Colorado School of Public Health, Aurora, CO, ⁴University of Colorado, Denver, CO, ⁵University of Colorado Denver Anschutz Medical Campus, Denver, CO, ⁶Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Women develop RA ~3 times more often than men. The etiology of this sex difference remains largely unexplained. Generation of anti-citrullinated protein antibodies (ACPA)…
Abstract Number: 0623 • ACR Convergence 2022
Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk
Edoardo Prediletto¹, Cankut Cubuk², Elena Pontarini³, Felice Rivellese², Alessandra Nerviani², Davide Lucchesi³, Mattia Caliste¹, Elisa Corsiero¹, Manzoor Ahmed³, rebecca hands³, Myles Lewis², Costantino Pitzalis² and Michele Bombardieri⁴, ¹Wlliam Harvey Research Institute Queen Mary University on London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom, ³William Harvey Research Institute, London, United Kingdom, ⁴Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom
Background/Purpose: Despite advances in the treatment of Rheumatoid Arthritis (RA), synthetics and biologicals drugs are ineffective in ~40% of patients. The origin of this refractoriness…
Abstract Number: 0751 • ACR Convergence 2022
Accessing Telehealth and In-Person Healthcare During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis
Smruthi Ramachandran¹, Jenny Leese², Stephanie Therrien³, Catherine L. Backman¹, Jasmin Ma⁴, Kelly English⁵, Eileen Davidson⁶, Shanon McQuitty⁷, Alison Hoens⁵, Cheryl Koehn⁸, James Gavin⁹, jo Adams⁹ and Linda Li¹, ¹University of British Columbia, Vancouver, BC, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada/University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Patient Advisory Board of Arthritis Research Canada, Vancouver, BC, Canada, ⁶Arthritis Patient Advisory Board of Arthritis Research Canada, Burnaby, BC, Canada, ⁷Arthritis Patient Advisory Board of Arthritis Research Canada, Richmond, BC, Canada, ⁸Arthritis Consumer Experts, Vancouver, BC, Canada, ⁹University of Southampton, Southampton, United Kingdom
Background/Purpose: The COVID-19 pandemic has provided opportunity to increase integration of virtual healthcare with in-person medical practices. Individuals with rheumatoid arthritis (RA) continue to self-manage…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].